These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 17589188)

  • 1. Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures.
    Benzie AA; Bansi LK; Sabin CA; Portsmouth S; Hill T; Johnson M; Gilson R; Easterbrook P; Gazzard B; Fisher M; Orkin C; Dunn D; Delpech V; Taylor GP; Walsh JC; Phillips AN;
    AIDS; 2007 Jul; 21(11):1423-30. PubMed ID: 17589188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
    Geretti AM; Smith C; Haberl A; Garcia-Diaz A; Nebbia G; Johnson M; Phillips A; Staszewski S
    Antivir Ther; 2008; 13(7):927-36. PubMed ID: 19043927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with viral rebound among highly treatment-experienced HIV-positive patients who have achieved viral suppression.
    Smith CJ; Phillips AN; Dauer B; Johnson MA; Lampe FC; Youle MS; Tyrer M; Staszewski S
    HIV Med; 2009 Jan; 10(1):19-27. PubMed ID: 19018880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virological rebound after suppression on highly active antiretroviral therapy.
    Mocroft A; Ruiz L; Reiss P; Ledergerber B; Katlama C; Lazzarin A; Goebel FD; Phillips AN; Clotet B; Lundgren JD;
    AIDS; 2003 Aug; 17(12):1741-51. PubMed ID: 12891060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?
    Bansi LK; Benzie AA; Phillips AN; Portsmouth S; Hill T; Leen C; Schwenk A; Johnson M; Anderson J; Gilson R; Easterbrook P; Gazzard B; Fisher M; Orkin C; Porter K; Pillay D; Taylor GP; Walsh JC; Sabin CA;
    AIDS; 2008 Jan; 22(3):349-56. PubMed ID: 18195561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression.
    Phillips AN; Staszewski S; Lampe F; Youle MS; Klauke S; Bickel M; Sabin CA; Doerr HW; Johnson MA; Loveday C; Miller V; ;
    J Infect Dis; 2002 Oct; 186(8):1086-91. PubMed ID: 12355358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A simple self-reported adherence tool as a predictor of viral rebound in people with viral suppression on antiretroviral therapy.
    O'Connor JL; Gardner EM; Esser S; Mannheimer SB; Lifson AR; Telzak EE; Phillips AN;
    HIV Med; 2016 Feb; 17(2):124-32. PubMed ID: 26186609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy.
    Doyle T; Smith C; Vitiello P; Cambiano V; Johnson M; Owen A; Phillips AN; Geretti AM
    Clin Infect Dis; 2012 Mar; 54(5):724-32. PubMed ID: 22238167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level.
    Lima VD; Bangsberg DR; Harrigan PR; Deeks SG; Yip B; Hogg RS; Montaner JS
    J Acquir Immune Defic Syndr; 2010 Dec; 55(4):460-5. PubMed ID: 20838225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals.
    Phillips AN; Miller V; Sabin C; Cozzi Lepri A; Klauke S; Bickel M; Doerr HW; Hill A; Staszewski S
    AIDS; 2001 Dec; 15(18):2379-84. PubMed ID: 11740188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of a prescription-based measure of antiretroviral therapy adherence to predict viral rebound in HIV-infected individuals with viral suppression.
    Cambiano V; Lampe FC; Rodger AJ; Smith CJ; Geretti AM; Lodwick RK; Holloway J; Johnson M; Phillips AN
    HIV Med; 2010 Mar; 11(3):216-24. PubMed ID: 20002781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substance use patterns and HIV-1 RNA viral load rebound among HIV-positive illicit drug users in a Canadian setting.
    Ladak F; Socias E; Nolan S; Dong H; Kerr T; Wood E; Montaner J; Milloy MJ
    Antivir Ther; 2019; 24(1):19-25. PubMed ID: 30230474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Markov model for the effects of virological failure on HIV/AIDS progression in tuberculosis co-infected patients receiving antiretroviral therapy in a rural clinic in northern South Africa.
    Shoko C; Chikobvu D; Bessong PO
    S Afr Med J; 2020 Mar; 110(4):313-319. PubMed ID: 32657744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salvage lopinavir-ritonavir therapy in human immunodeficiency virus-infected children.
    Resino S; Bellón JM; Ramos JT; Navarro ML; Martín-Fontelos P; Cabrero E; Muñoz-Fernández MA
    Pediatr Infect Dis J; 2004 Oct; 23(10):923-30. PubMed ID: 15602192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Viral load in HIV-infected children on high activity antiretroviral therapy].
    Resino S; Bellón JM; León JA; Resino R; Muñoz-Fernández MA;
    Med Clin (Barc); 2007 Jan; 128(2):49-51. PubMed ID: 17266901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and immunologic outcome in patients with human immunodeficiency virus infection, according to virologic efficacy in the year after virus undetectability, during antiretroviral therapy.
    Abgrall S; Duval X; Joly V; Descamps D; Matheron S; Costagliola D;
    Clin Infect Dis; 2003 Dec; 37(11):1517-26. PubMed ID: 14614675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes after viral load rebound on first-line antiretroviraltreatment in children with HIV in the UK and Ireland: an observational cohort study.
    Childs T; Shingadia D; Goodall R; Doerholt K; Lyall H; Duong T; Judd A; Gibb DM; Collins IJ;
    Lancet HIV; 2015 Apr; 2(4):e151-8. PubMed ID: 26413561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Raised viral load in patients with viral suppression on highly active antiretroviral therapy: transient increase or treatment failure?
    Moore AL; Youle M; Lipman M; Cozzi-Lepri A; Lampe F; Madge S; Nesaratnam S; Tyrer M; Cuthbertson Z; Ransom D; Loveday C; Johnson MA; Phillips AN;
    AIDS; 2002 Mar; 16(4):615-8. PubMed ID: 11873005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The rate of viral rebound after attainment of an HIV load <50 copies/mL according to specific antiretroviral drugs in use: results from a multicenter cohort study.
    Smith CJ; Phillips AN; Hill T; Fisher M; Gazzard B; Porter K; Gilson R; Easterbrook P; Matthias R; Scullard G; Johnson MA; Sabin CA;
    J Infect Dis; 2005 Oct; 192(8):1387-97. PubMed ID: 16170756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study.
    Ledergerber B; Egger M; Opravil M; Telenti A; Hirschel B; Battegay M; Vernazza P; Sudre P; Flepp M; Furrer H; Francioli P; Weber R
    Lancet; 1999 Mar; 353(9156):863-8. PubMed ID: 10093977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.